June 10, 2019 11:02 AM EDTUpdated 12:19 PM

Bat­tered by le­gal ex­pens­es, opi­oid drug­mak­er In­sys files for bank­rupt­cy days af­ter $225M deal to set­tle gov­ern­ment probes

Natalie Grover

Reporter

To no­body’s sur­prise, con­tro­ver­sial opi­oid drug­mak­er In­sys is fil­ing for bank­rupt­cy.

Last week, the com­pa­ny $IN­SY agreed to pay $225 mil­lion to set­tle the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

New fund will pres­sure flail­ing biotechs, as in­vestor frus­tra­tion boils over

Ake­so shares new da­ta sug­gest­ing it can beat Keytru­da on sur­vival, wins Chi­na ap­proval

Cari­bou lays off 32% of staff, cuts lu­pus cell ther­a­py pro­gram be­fore first pa­tient

Mer­ck KGaA clos­es in on Spring­Works deal at $3.5B price point

FDA chief Makary talks ex­pe­dit­ing drug ap­provals, RIFs and the abor­tion pill

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times